Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inotuzumab ozogamicin - Pfizer

Next Previous
Drug Profile

Inotuzumab ozogamicin - Pfizer

Alternative Names: BESPONSA; CMC-544; InO - Pfizer; PF-05208773; PF-5208773; WAY-207294

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celltech Group; Wyeth
  • Developer Pfizer
  • Class Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Chronic myeloid leukaemia
  • No development reported Acute biphenotypic leukaemia; Burkitt's lymphoma
  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for phase-I development in Acute-biphenotypic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Burkitt's-lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 26 Mar 2026 Preregistration for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In adolescents, In children, In infants, Monotherapy) in European Union (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top